XOMA Corp. has earned a $2 million milestone payment from Takeda Pharmaceutical Company as the first patient has been dosed in its Phase 2 study to evaluate safety, tolerability, and efficacy of mezagitamab (TAK-079) in generalized myasthenia gravis (MG).  In 2006, XOMA and Takeda partnered to identify therapeutic antibodies that Takeda would advance into clinical development. Mezagitamab is an anti-CD38 antibody that resulted from the companies’ collaboration. XOMA may receive as much as $16...